Opinion|Videos|February 18, 2025
Real-World Observations With Pirtobrutinib and New Data From the BRUIN CLL-321 Trial at ASH 2024
Panelists discuss how real-world experience with pirtobrutinib generally aligns with the BRUIN study’s progression-free survival (PFS) data while sharing insights about common reasons for discontinuation and interpreting updated BRUIN CLL-321 trial results from ASH 2024 that may influence clinical decision-making regarding pirtobrutinib use in practice.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Have you observed similar median PFS duration with pirtobrutinib as reported out in the BRUIN study? What are your top clinical observations for patients having to discontinue or switch off pirtobrutinib?
- The BRUIN CLL-321 trial had data updates at ASH; could you sharekey highlights and your impressions so far and whether you anticipate this data to influence your use of pirtobrutinib in the real-life clinical setting?
Advertisement
Related to this article
FDA has granted fast track designation to LYT-200 plus a hypomethylating agent in relapsed/refractory high-risk myelodysplastic syndromes.
Toon Van Gorp, MD, PhD, discusses key data with TUB-040 in platinum-resistant ovarian cancer and next steps for development.
Japan approved subcutaneous pembrolizumab and berahyaluronidase alfa across all indications for which intravenous pembrolizumab is approved in the country.
New research reveals how cancers carrying mutations in the p53 tumor-suppressor protein can hide those mutations from T cells.
Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.
Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5